One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Athersys logo
Athersys ATHX
report update icon

Quarterly report 2023-Q3
added 06-27-2026

Athersys Financial Ratios 2022-2008 | ATHX

Brief overview of Athersys's valuation and returns

This overview follows the five latest available observations from 2009 through 2022.

Market valuation is represented by EV/EBITDA 0.12x (median 0.19x), P/S 1.46x (median 10.62x), P/B 0.13x (median 4.72x). Valuation is roughly 61.2% below five-year reference levels. The discount may reflect opportunity or higher perceived risk.

The latest available business-quality ratios are ROE 3%, ROA -2.6%, ROCE 3.2%. Current return ratios are negative, materially weakening the fundamental profile.

PEG is 1.01x. Price relative to expected growth is in a moderate range.

The cash cycle lengthened by 66.6 days to 73 days. Operations require more funding.

Overall assessment

Athersys trades below its own history, but weak profitability may explain the discount. Low multiples alone do not prove undervaluation.

Annual Financial Ratios Athersys

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

P/E

- -0.1 -0.2 -4.1 -8.4 -4.8 -6.6 -8.9 -9.0 -7.1 -3.4 -3.4 - - -

P/S

- 1.5 10.6 32.3 8.4 41.4 5.9 12.2 122.8 89.4 5.7 4.5 - - -

EPS

-6.1 -9.7 -10.5 -0.3 -0.2 -0.1 -0.1 -0.2 -0.3 -0.5 -0.5 -0.6 -0.6 -0.8 -

EV (Enterprise Value)

-9.04 M -29.3 M -7.9 M 165 M 171 M 134 M 94.8 M 129 M 181 M 200 M 31.6 M 46.6 M -2.1 M -11.2 M -12.6 M

EBITDA per Share

-6.33 -9.55 -10.3 -0.3 -0.18 -0.29 -0.17 -0.21 -0.37 -0.42 -0.48 -0.58 -0.59 - -

EV/EBITDA

0.1 0.3 0.1 -3.7 -7.1 -4.1 -6.5 -7.6 -6.3 -8.3 -2.0 -3.4 0.2 0.7 -

PEG

- -0.0 -0.0 -0.55 1.01 1.48 0.32 0.51 -0.16 0.41 -0.13 -1.89 - - -

P/B

- 0.1 0.5 7.8 4.7 6.6 9.1 7.4 9.5 11.0 2.5 6.4 - - -

P/CF

- -0.1 -0.2 -5.2 -15.3 -6.4 -9.3 -6.9 -6.2 -9.6 -2.8 -3.2 - - -

ROE %

304.11 -531.22 -251.15 -191.58 -56.32 -137.92 -137.17 -83.26 -105.68 -155.10 -72.78 -188.35 -126.34 -81.06 -

ROA %

-261.56 -144.48 -131.90 -107.00 -39.34 -95.98 -80.47 -65.35 -76.89 -89.92 -53.38 -87.55 -59.55 - -

ROCE %

322.88 -531.85 -213.09 -157.79 -54.15 -141.57 -123.32 -84.28 -120.75 -82.02 -69.19 -166.41 -127.83 -82.37 -

Current Ratio

- - 2.1 2.3 3.3 3.3 2.4 4.6 3.7 2.4 3.8 1.9 - - -

DSO

73.0 46.8 22.6 8.5 6.4 58.3 10.1 16.1 136.5 75.6 24.7 53.2 - - -

Operating Cycle

73.0 46.8 22.6 8.5 6.4 58.3 10.1 16.1 136.5 75.6 24.7 53.2 - - -

Cash Conversion Cycle

73.0 46.8 22.6 8.5 6.4 58.3 10.1 16.1 136.5 75.6 24.7 53.2 - - -

All numbers in USD currency

Quarterly Financial Ratios Athersys

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.15 -0.62 -0.43 - -1.15 -90 -0.09 -0.09 -0.07 -0.1 -0.13 -0.11 -0.11 -0.1 -0.1 -0.06 -0.08 -0.06 -0.09 -0.08 -0.07 0.05 -0.08 -0.11 -0.06 -0.06 -0.06 -0.08 -0.07 -0.08 0.06 0.04 -0.08 -0.01 -0.16 -0.08 -0.06 0.01 -0.15 -0.15 -0.1 -0.11 -0.18 -0.07 -0.12 -0.13 -0.17 -0.18 -0.1 -0.14 -0.18

EBITDA per Share

-0.28 -0.63 -0.4 - -1.36 -0.09 -0.09 -2.23 -0.07 -0.1 -0.13 -0.11 -0.11 -0.09 -0.1 -0.06 -0.08 -0.06 -0.09 -0.08 -0.07 0.05 -0.08 -0.11 -0.06 -0.06 -0.06 - -0.07 -0.09 0.08 - -0.08 -0.08 -0.09 - -0.09 -0.09 -0.1 - -0.1 -0.11 -0.13 - -0.14 -0.12 -0.14 - -0.13 -0.14 -0.12

ROE %

152.37 532.74 -6738.28 -6763.47 -6896.11 -7200.71 -7749.48 -581.43 -519.60 -425.35 -320.31 -334.18 -306.02 -306.30 -321.40 -274.32 -257.93 -148.92 -68.50 -54.65 -84.43 -92.86 -129.28 -127.18 -134.89 -144.57 -155.67 -93.91 -11.96 -16.39 13.94 -94.18 -143.76 -119.45 -112.42 -85.50 -103.55 -134.79 -187.52 -221.01 -187.58 -315.61 -347.53 -329.39 -371.67 -216.93 -159.56 -159.34 -22.13 -25.10 -53.85

ROA %

-248.69 -328.20 -254.26 -218.15 -254.23 -306.27 -242.93 -230.12 -231.24 -222.87 -195.28 -198.72 -185.35 -176.29 -179.46 -161.41 -155.93 -97.50 -45.46 -40.14 -60.79 -68.48 -97.14 -95.45 -93.84 -97.26 -103.05 -73.68 -22.00 -17.49 4.62 -40.84 -77.95 -70.28 -65.81 -58.88 -64.71 -79.33 -109.02 -124.97 -108.05 -114.09 -113.88 -97.37 -112.73 -90.91 -77.03 -78.48 -12.41 -13.96 -25.03

ROCE %

180.34 365.62 -6958.34 -6981.99 -7114.40 -7270.28 -7549.65 -329.14 -266.61 -261.87 -217.74 -231.90 -204.92 -200.09 -201.30 -154.44 -138.32 -112.43 -70.66 -56.21 -85.95 -94.25 -130.61 -130.92 -113.16 -121.87 -37.47 -15.57 -58.79 -52.92 -52.34 -112.37 -139.48 -119.85 -111.86 -75.61 -124.37 -149.77 -178.80 -153.89 -371.83 -403.29 -402.62 -350.00 -379.86 -188.91 -148.12 -96.29 -29.86 -27.00 -39.42

DSO

- - - - 421.1 11.8 - - - - - - - - - - - - 8.3 25.2 22.0 3.1 57.6 50.4 150.4 161.9 73.4 41.6 138.8 103.8 3.1 2.9 310.7 1102.4 220.4 263.9 214.9 189.2 91.2 48.2 75.6 83.8 134.8 18.5 51.3 18.9 18.1 15.4 11.7 20.9 -

Operating Cycle

- - - - 421.1 11.8 - - - - - - - - - - - - 8.3 25.2 22.0 3.1 57.6 45.7 134.0 79.9 36.8 55.5 182.8 95.5 2.8 3.1 316.0 579.4 65.8 263.9 214.9 189.2 91.2 51.6 76.4 83.1 141.3 19.5 44.0 16.8 19.6 24.5 26.7 25.8 -

Cash Conversion Cycle

- - - - 421.1 11.8 - - - - - - - - - - - - 8.3 25.2 22.0 3.1 57.6 45.7 134.0 79.9 36.8 55.5 182.8 95.5 2.8 3.1 316.0 579.4 65.8 263.9 214.9 189.2 91.2 51.6 76.4 83.1 141.3 19.5 44.0 16.8 19.6 24.5 26.7 25.8 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Athersys, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Repare Therapeutics Repare Therapeutics
RPTX
- - $ 112 M canadaCanada
Sesen Bio Sesen Bio
SESN
- 7.29 % $ 127 M usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
- - $ 26.8 M usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
- 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
- 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
- - $ 13 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Exicure Exicure
XCUR
$ 1.05 -7.08 % $ 6.61 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 0.98 0.51 % $ 98.3 M franceFrance
AbCellera Biologics AbCellera Biologics
ABCL
$ 11.82 3.96 % $ 3.53 B canadaCanada
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 58.02 -0.58 % $ 7.76 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 55.95 -1.2 % $ 10.7 B usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 29.25 0.97 % $ 1.94 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 3.67 1.38 % $ 44.8 M israelIsrael
Jaguar Health Jaguar Health
JAGX
$ 2.04 -5.12 % $ 4.76 M usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
$ 2.55 -0.58 % $ 200 M israelIsrael
uniQure N.V. uniQure N.V.
QURE
$ 22.43 -2.94 % $ 1.29 B niderlandNiderland
Stoke Therapeutics Stoke Therapeutics
STOK
$ 25.04 -2.57 % $ 1.48 B usaUSA
Xencor Xencor
XNCR
$ 25.18 -2.55 % $ 1.87 B usaUSA
Annexon Annexon
ANNX
$ 3.75 -1.57 % $ 582 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 1.78 -2.73 % $ 2.93 M israelIsrael
Incyte Corporation Incyte Corporation
INCY
$ 115.71 -1.04 % $ 22.6 B usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 12.28 -2.15 % $ 14.8 B australiaAustralia
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
$ 9.21 -5.73 % $ 741 M usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
$ 523.93 -2.1 % $ 134 B usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 4.4 -1.57 % $ 233 M usaUSA
AbbVie AbbVie
ABBV
$ 285.64 0.24 % $ 505 B usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.16 -4.11 % $ 259 K usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 0.57 0.84 % $ 147 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.2 -0.24 % $ 805 M canadaCanada
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 19.73 -2.86 % $ 3.32 B usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.44 -9.72 % $ 183 M schweizSchweiz
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 25.51 4.51 % $ 3.87 B usaUSA
EyePoint Pharmaceuticals EyePoint Pharmaceuticals
EYPT
$ 0.4 -5.51 % $ 29.3 K usaUSA
Seagen Seagen
SGEN
- - $ 42.2 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 37.0 -0.51 % $ 2.14 B usaUSA